History

  • 2012

    Break Through

    1. The renowned medical journal, European Urology, publishes pivotal results as to the software EXINI bone and Bone Scan Index (BSI).
    2. Bone Scan Index (BSI) is recognised as a vital imaging biomarker for advanced breast- and prostate cancer.
    3. FDA-approval is granted for EXINI bone
    4. The first unit of EXINI boneBSI is installed in the USA, at Memorial Sloan-Kettering Cancer Centre in New York.
    5. Fujifilm reaches 700 installed units of EXINI bone in Japan.
    6. VINNOVA, Sweden’s Governmental Agency for Innovation Systems grants financial support and appoints EXINI as corporate partner in a multimillion project exploring medical cloud services.
    7. EXINI engages in a partnership with Active Biotech targeting clinical trials.
    8. EXINI® becomes Registered Trademark.

     

  • 2011

    The Japanese market

    1. EXINI signs a vital agreement with Fujifilm RI Pharma, Co, Ltd.
    2. EXINI boneTM is distributed as “BoneNavi” throughout Japan.
    3. Fujifilm log 300 installed units in Japan.
    4. A Letter of Intent is signed with Fujifilm regarding the EXINI heartTM software.
    5. A new issue of shares is carried out.
    6. EXINI is listed at NASDAQ OMX First North.

  • 2010

    New Leadership

    1. Magnus Aurell becomes CEO of EXINI.
    2. EXINI dat becomes CE-certified.
    3. A new distribution agreement is signed for the UK.
    4. New market strategy: to approach OEM and hospitals concurrently.

  • 2009

    Fourth Software

    1. 500% increase of sales compared to 2008.
    2. EXINI boneTM is completed and launched in April.
    3. Finalization of the fourth software, EXINI dat.
    4. An upgraded product portfolio is introduced to all markets.
    5. A new issue of shares is carried out.
    6. EXINI is listed on AktieTorget (Equities Market Place).

  • 2008

    Third Software

    1. A new version of EXINI heart is launched in October.
    2. Development of a third software, EXINI bone, is launched.
    3. EXINI changes its business model to incorporate annual software upgrades.
    4. Recruitments to sales division for upcoming efforts in -09.

  • 2007

    Name Change

    1. WeAidU becomes ISO 13485 certified by German TÜV.
    2. Both CARE heart and CARE brainTM becomes CE-certified products.
    3. WeAidU changes name to EXINI Diagnostics.
    4. The complete product family is renamed.
    5. EXINI recruits a new CEO with substantial market experience from the US.
    6. Cooperation with the US clinic Mayo in Rochester, Minnesota.
    7. EXINI heart and EXINI brain are submitted for FDA approval.

  • 2006

    New Owner & Second Software

    1. Distribution agreement signed for Denmark.
    2. WeAidU’s second prototype, Care brainTM , is demonstrated at the annual meeting for the Swedish Society for Nuclear Medicine and in Athens at the European Association for Nuclear Medicine (EANM).
    3. Decision to get WeAidU ISO 13485 certified.
    4. Bo Håkansson (Chairman of the Board) becomes the major shareholder in WeAidU.

  • 2005

    Software Upgrade

    1. An upgraded version of CARE Heart is launched in springtime.
    2. Renewed distribution agreement with GE Health Care.
    3. 50% market penetration for CARE heart in Sweden and 15% in Finland.
    4. Upcoming distribution agreements for additional European countries.

  • 2004

    Market Penetration

    1. WeAidU’s turnover doubled.
    2. The first distribution agreement signed with Amersham Healthcare in Sweden and Denmark.
    3. The CARE heart software penetrates 35% of the Swedish market
    4. R & D-efforts for the CARE-product family is initiated.
    5. Negotiations with major stakeholders within the fields of Positron Emission Tomography (PET), Brain and Bone Imaging.

  • 2002

    First Software

    1. To evaluate the CARE heart software, a Nordic scientific/medical collaboration is formed.
    2. Participants: Rigshospitalet in Copenhagen, Odense University Hospital, University of TromsØ, Kuopio University Hospital and Lund University.
    3. First product launch: CARE heart in Scandinavia, Belgium and in the U.K. during the fall of -02.

  • 2000

    Prototypes

    1. The first prototype of the CARE heartTM software is developed.
    2. This prototype is demonstrated throughout Europe at trade fairs and congresses.
    3. WeAidU forms a Medical Board.

  • 1999

    Founding the Company

    1. EXINI is created under its first name WeAidU.
    2. Main focus: to create a comprehensive decision support system.
    3. Initial project: automated interpretation of diagnostic heart images.
    4. Successful results: acquired techniques for advanced image processing, artificial neural networks, and an extensive and thoroughly evaluated database.

  • 1994

    Founding Fathers

    1. Professor Lars Edenbrandt, physician & clinical expert.
    2. Professor Carsten Peterson, theoretical physicist and Artificial Neural Networks expert.
    3. Professor Karl Åström, mathematician and expert in image analysis.
    4. Pivotal collaboration in the field of automated analysis and interpretation of patient’s data.

  • The origin

    LUMI Research

    1. The formation LUMI in the early 1990s, www.lumi.lu.se (Lund University Research Programme in Medical Informatics, an interdisciplinary research group).
    2. LUMI has produced seven PhD’s, six Master’s Thesis and well over 50 publications in renowned international scientific journals.
    3. EXINI’s products are based on LUMI’s internationally acclaimed research.